Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYou've started losing weight on semaglutide and, quite reasonably, you're wondering whether the scales are telling the whole story. Specifically: is some of that loss coming from muscle? And can you gain muscle on semaglutide at the same time as losing fat? These are among the most practical questions people ask once treatment is underway — and the answers matter for your long-term health, not just the number on the dial. Semaglutide (sold as Wegovy in the UK for weight management) reduces appetite through GLP-1 receptor activation, which creates the calorie deficit that drives weight loss. What that deficit does to muscle tissue depends significantly on what you eat and how you move — factors that remain very much in your hands. These are prescription-only medicines, and any treatment should be supported by a prescriber and, ideally, a dietitian who can help you protect lean mass throughout.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the situation many people find themselves in around week four or five of treatment. The nausea has mostly settled, appetite is genuinely lower, and meals that used to feel normal now feel like too much. That's the medicine working. But a quieter appetite also means it's easy to eat too little protein without realising it, and protein is the raw material your body uses to maintain and build muscle.
When the body runs a calorie deficit (which is how semaglutide drives weight loss) it draws on stored energy. Ideally, most of that comes from fat. But lean tissue, including muscle, is also broken down for fuel if protein intake is insufficient or if resistance training isn't signalling to the body that muscle is worth keeping. The effect of semaglutide on muscle mass isn't dramatic in the way rapid crash-dieting can be, but it isn't zero either.
A quick habit worth building: at the end of each meal, check whether you've included a source of protein, eggs, fish, meat, dairy, legumes, tofu. It takes about thirty seconds and it's one of the simplest ways to catch a day heading in the wrong direction before it becomes a pattern. Aim for consistency across the week rather than perfection at every meal.
Most clinical trial data on semaglutide focuses on total body weight and cardiovascular markers, so the muscle-specific picture is still being fleshed out by ongoing research. What the evidence does consistently show is that lifestyle behaviours (particularly resistance exercise and adequate protein) have a real moderating effect on how much lean mass is preserved during weight loss treatment.
The honest answer is: for most people, preserving muscle is the primary goal, and genuine muscle gain while on semaglutide is possible but takes deliberate effort. Muscle growth (hypertrophy) requires a protein surplus at the muscle level, progressive resistance training, and sufficient recovery. Doing that while also maintaining the calorie deficit that makes semaglutide effective is physiologically demanding.
That said, a meaningful group of people (particularly those who are new to resistance training) can make strength and muscle gains even in a mild deficit, a phenomenon researchers sometimes call "newbie gains." If you haven't done consistent weight-bearing exercise before, introducing it alongside semaglutide treatment may produce noticeable improvements in muscle function alongside fat loss. The question of whether you can gain muscle on Wegovy specifically is covered in detail on its own page, including what the trial data currently shows.
For people who already train regularly, the more realistic and arguably more valuable outcome is arriving at a lower body weight while retaining as much muscle as possible. That means leaner, not smaller, and it's a genuinely good health outcome. Muscle mass is strongly associated with metabolic health, insulin sensitivity and long-term mobility, so protecting it during weight loss is worth treating as a priority, not an afterthought.
Strength training at least two to three times per week, with a focus on compound movements (squats, rows, presses), combined with protein targets of roughly 1.2–1.6 g per kilogram of body weight daily, represents the current consensus approach. Discuss specific targets with your prescriber or a registered dietitian, since individual circumstances vary.
Some loss of lean mass during significant weight reduction is normal and expected, it happens with any method of weight loss, not just with semaglutide. The relevant question is whether the proportion of weight lost as muscle is higher, lower or similar compared with other approaches. Early data from the STEP programme and subsequent analyses suggest the proportion of weight lost as lean mass on semaglutide is broadly comparable to, or somewhat lower than, what's seen with equivalent calorie restriction alone.
The risk of muscle loss on semaglutide is real but manageable, and it's heavily influenced by behaviour. Rapid weight loss, very low protein intake, and physical inactivity all push the proportion of lean-mass loss upward. Gradual, steady weight loss (which semaglutide generally produces via its titrated dosing schedule) combined with resistance training and adequate protein pulls it in the other direction.
It's also worth noting that the Wegovy and muscle loss conversation is still evolving scientifically. Tirzepatide (Mounjaro), the dual GIP and GLP-1 agonist, has shown a higher proportion of fat-specific loss in some analyses, though head-to-head muscle-composition data are limited. If muscle preservation is a particular concern for you, that's a conversation worth having with a prescriber rather than drawing conclusions from trial headlines.
For a thorough overview of what semaglutide is and how it works in the UK licensed context, the semaglutide overview page covers the mechanism, eligibility and how to start treatment through a regulated pharmacy. If cost is part of your thinking, the Wegovy pricing context page explains what legitimate private treatment typically includes.
Nausea, reduced appetite and occasional fatigue are the most common experiences at the start of treatment and after dose increases, as the NHS semaglutide page outlines. These are relevant to muscle health because they can suppress the motivation or capacity to exercise and eat enough on difficult days.
A few points worth knowing. Fatigue on treatment days is fairly common and doesn't mean the medicine isn't working, timing your injection and planning lighter activity on days when you tend to feel it most can help. Dehydration from GI symptoms can impair exercise performance and recovery; keeping fluid intake steady matters more than it might seem.
Some people also ask about mood on treatment, whether low energy is partly psychological. There's separate reading on semaglutide and anxiety if that's relevant to your experience. It isn't directly related to muscle, but wellbeing and exercise motivation are genuinely connected.
The NHS guidance on semaglutide side effects is the right first reference for anything that concerns you clinically. If you're approaching treatment and want to talk through how to structure your exercise and nutrition alongside it, checking your eligibility with our prescribers is a sensible starting point, that's the kind of practical question they field every day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.